Tiziana Life Sciences

1. Intranasal foralumab Alzheimer's Ph2 readout2026Intranasal foralumab Alzheimer's Ph2 readout, 2026, notable
2. Intranasal foralumab na-SPMS toplineOct 2026Intranasal foralumab na-SPMS topline, Oct 2026, thesis-defining
3. Tiziana corporate updateOct 2026Tiziana corporate update, Oct 2026, routine
4. Intranasal foralumab MSA FDA decisionDec 29, 2026Intranasal foralumab MSA FDA decision, Dec 29, 2026, material
5. Frexalimab Sanofi readout2027Frexalimab Sanofi readout, 2027, material
6. Coya 302 ALS Ph2/3 topline2Q 2027Coya 302 ALS Ph2/3 topline, 2Q 2027, material
7. Intranasal foralumab MSA readoutApr 1, 2027Intranasal foralumab MSA readout, Apr 1, 2027, notable
8. Intranasal foralumab ALS readoutJul 2027Intranasal foralumab ALS readout, Jul 2027, notable
9. Amlenetug MSA Ph3 readout3Q 2027Amlenetug MSA Ph3 readout, 3Q 2027, notable
10. Foralumab composition-of-matter patents patent expiryNov 6, 2027Foralumab composition-of-matter patents patent expiry, Nov 6, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.